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Abstract
DYT1 dystonia is a debilitating neurological disease characterized by involuntary twisting movements. The disease is caused
by an in-frame deletion (GAG, ‘‘DE’’) mutation in the TOR1A gene that encodes the torsinA protein. Intriguingly, only 30% of
mutation carriers exhibit motor symptoms despite the fact that functional brain imaging studies show abnormal brain
metabolism in all carriers. Because genetic modifiers may be a determinant of this reduced penetrance, we examined the
genetic contribution of three different inbred strains of mice on the DYT1 mutation in animals that are homozygous
(Tor1a
DE/DE) or heterozygous (Tor1a
DE/+; disease state) for the disease-causing DE mutation. We find that the DBA/2J, C57BL/
6J, and CD1-ICR contribution of genes significantly alter lifespan in Tor1a
DE/DE mice, which die during the first few days of
life on the 129S6/SvEvTac (129) background. The C57BL/6J (B6) strain significantly decreases life expectancy of Tor1a
DE/DE
animals but, like 129S6/SvEvTac Tor1a
DE/+ mice, congenic C57BL/6J Tor1a
DE/+ mice do not exhibit any motor abnormalities.
In contrast, the DBA/2J (D2) strain significantly increases life expectancy. This effect was not present in congenic DBA/2J
Tor1a
DE/DE mice, indicating that the extended lifespan of F2 129/D2 mice was due to a combination of homozygous and
heterozygous allelic effects. Our observations suggest that genetic modifiers may alter the penetrance of the DE mutation,
and that mapping these modifiers may provide fresh insight into the torsinA molecular pathway.
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Introduction
Dystonia is defined as abnormal involuntary movements that
are prolonged, twisting in nature and frequently stereotypic and
repetitive. Dystonia occurs as an isolated symptom without
evidence of brain injury (‘‘primary’’ dystonia) or as a consequence
of pathologic insults to the basal ganglia or related structures
(‘‘secondary’’ dystonia). Primary and secondary dystonia may be
treated with similar medications (e.g. anticholinergics) and both
respond to deep brain stimulation therapy [1]. These facts, and the
characteristic dystonic postures that result from diverse etiologies,
suggest that primary and secondary forms of dystonia may share a
common downstream abnormality, perhaps a stereotyped disrup-
tion of basal ganglia output (from the internal segment of the
globus pallidus/substantia nigra pars reticulata).
The most common genetic form of primary dystonia, DYT1
dystonia, is a neurodevelopmental disorder caused by an in-frame
deletion (GAG, ‘‘DE’’) in the TOR1A gene that results in the loss
of a glutamic acid in the C-terminus of torsinA [2,3]. DYT1
dystonia is dominantly inherited but abnormal movements affect
only 30% of mutation carriers. Despite this incomplete pene-
trance, 2-deoxyglucose studies show that all carriers exhibit
abnormal brain metabolism, with increased metabolic activity in
the cerebellum, putamen/globus pallidus, and supplementary
motor cortex [4,5]. Similarly, magnetic resonance diffusion tensor
imaging (DTI) shows white matter abnormalities associated with
reduced integrity of the cerebellothalamocortical motor pathway
in all DYT1 mutation carriers [6,7]. These clinical studies
highlight that the apparent penetrance of a mutation depends
greatly on the phenotype being assessed, and demonstrate that all
DE mutation carriers have abnormally functioning brains.
The factors that determine conversion from sub-clinical
‘‘endophenotype’’ to overt disease remain unknown. Similarly,
nearly all animals harboring monogenic mutations show signifi-
cant phenotypic variability, likely due to multiple intermingling
factors such as environment, allelic heterogeneity and stochastic
effects, as well as the presence of modifier genes [8]. Indeed, a
focus on the effect of this ‘‘genetic background noise’’ [8] is
emerging in an effort to understand what makes some individuals
more susceptible than others to certain disease-causing mutations.
The features of DYT1 dystonia (monogenic mutation, incomplete
penetrance) suggest that this disease may be an excellent model
system in which to examine these issues. Possible genetic modifiers
of the torsinA pathway include torsinB, which has redundant
functions [9], and other torsinA-interacting proteins, including
LAP1, LULL1 [10] and printor [11]. Importantly, identifying
factors that modulate DE-torsinA phenotypes has the potential not
only to provide insight into disease mechanism, but also may
suggest alternative strategies for disease treatment and prevention.
Given the many factors that can modulate disease phenotypes, it
can be exceedingly difficult to model diseases with limited
penetrance, such as DYT1 dystonia. To date, etiologic mouse
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features or evidence of pathology such as neuronal loss, including
transgenic mice expressing human mutant torsinA (hMT)
[12,13,14], and heterozygous knock-in mice in which the DGAG
mutation has been introduced in the endogenous mouse Tor1a
gene [15,16]. Furthermore, homozygous mutant torsinA expres-
sion results in perinatal lethality [17] preventing behavioral
analysis of these mice. Therefore, mouse models of DYT1
dystonia suffer from an ‘‘all or none’’ effect of mutated torsinA
in mice. We set out to explore ways to: 1. Amplify any behavioral
abnormalities in the disease state mouse (heterozygous) or 2.
Temper the effects of homozygous Tor1a
DE/DE mouse (increase
lifespan to observe effects).
The lack of a consistent or clearly apparent phenotype may be
due in part to the variability in mouse backgrounds used in these
studies. Modifier genes present in certain strains may act to
suppress or exacerbate the effects of the DE mutation. Numerous
studies demonstrate that genetic background alters both baseline
and pharmacological responses in mice [18]. Modifier loci have
already been mapped for several neurological diseases in both
human and mouse. These diseases include tremor, dystonia,
epilepsy and Huntington’s disease. For example, in the kinesio-
genic mouse model of dystonia, Scn8a
medj mice exhibit striking
phenotypes on the C57BL/6J background with paralysis and
lethality by one month of age, while the C3H inbred strain
background causes a progressive dystonia and ataxia, but a normal
lifespan [19]. To begin to identify genetic modifiers of the torsinA
pathway, we utilized mice homozygous for the DE mutation
(Tor1a
DE/DE). These mice, which die on the day of birth [16], have
histologically normal-appearing brains, but electron microscopic
(EM) analysis shows a selective disruption of the neuronal nuclear
envelope (NE; referred to as ‘‘blebs’’) [16]. We used these
phenotypes (animal death, NE blebs) as an in vivo read-out of
torsinA function, and explored whether they were modified when
placed on distinct genetic backgrounds, a strategy similar to how
the rough eye phenotype is utilized in drosophila genetic studies.
We pursued an F1 intercross screening strategy to identify
background strains that amplify or suppress death or NE blebs.
Subsequently, we generated congenic mice on these different
genetic backgrounds to test for an effect of background on the
behavioral phenotype of Tor1a
DE/+ mice. We find that despite the
effect of C57BL/6J alleles on the survival of Tor1a
DE/DE mice,
these alleles did not cause a behavioral phenotype in the congenic
Tor1a
DE/+ mice (disease genotype).
Materials and Methods
Male mice were housed in groups of 5 and maintained on a 12-
hour light/dark schedule (lights on at 7:00 pm). Food and water
were provided ad libitum. Behavioral testing occurred during the
dark phase between 7:00 am and 5:00 pm. Animal testing was
conducted in accord with the National Institutes of Health
laboratory animal care guidelines and with the University
Committee on Use and Care of Animals at the University of
Michigan approval. The University of Michigan’s Institutional
Unit for Laboratory Animal Medicine (ULAM) provides veteri-
nary care to all animals used on campus. We ensured that all
animals used in this study were healthy and experienced minimal
discomfort. All protocols were approved prior to experimentation.
Specifically, experiments were described in protocol 10292.
Generation of Tor1a
DE/+ congenic mouse strains and
intercross breeding strategy
The Tor1a
DE/+mouse, with a targeted deletion of glutamic acid
(DE) in the encoded protein torsinA, was generated as previously
described [16] by gene targeting in ES cells from the 129S6/
SvEvTac (129) strain. Heterozygous 129-Tor1a
DE/+ mice were
mated to C57BL/6J (B6), DBA/2J (D2), and CD1-ICR (CD1) mice
toinitiate 3 linesofTor1a
DE/+miceondifferentgeneticbackgrounds.
F1 mice were intercrossed to generate F2 Tor1a
DE/DE mice with
genetic backgrounds that were ,50% of the original 129
background and ,50% of B6, D2, or CD1 background (referred
to as 129/B6, 129/D2, and 129/CD1, respectively).
To generate congenic B6?Tor1a
DE/+ mice, 129-Tor1a
DE/+
heterozygotes were repeatedly backcrossed to the B6 and D2
strains for more than 10 generations to generate two different
strains with 99.6–99.8% genetic identity with the B6 and D2
inbred strains.
Genotyping
Tail samples from mice were excised and boiled in 300 ml
50 mM NaOH at 95uC for 50 minutes. Denatured tails were
vortexed and mixed with 30 ml 1 M Tris pH 8.0 buffer to
neutralize and centrifuged for 10 minutes at maximum speed. Pre-
mixed PCR beads (PuReTaq Ready-To-Go PCR Beads, GE
healthcare) were resuspended in 24 ml of primer mix at final
concentration of 3.0 mg/ml and 1.0 ml of tail lysate supernatant.
Primer sequences and PCR parameters for genotyping are listed in
Table 1.
Sequencing genomic DNA
For sequencing of the Tor1a mouse gene, DNA was extracted
and purified from mouse tail samples using Qiagen DNeasy Blood
and Tissue kit per manufacturer’s instructions. Sequencing was
done using an ABI Model 3730 sequencer with the following
primers: 59- AAC AGA GCC AAC ACT CTG G-39 (forward) and
59-TGC TGT ACA AGA TCC TCC-39.
Table 1. Genotyping parameters for Tor1a knock-in mice.
Mutant animal Primers PCR parameters Product size
Tor1a
DE/+ Forward: 59-agtctgtggctggctctccc-39 95uC for 1 min WT=300 bp
Reverse: 59- cctcaggctgctcacaaccac-39 95uC for 15 sec Mut=340 bp
68uC for 30 sec
72uC for 30 sec
Repeat 38 times
72uC for 10 min
doi:10.1371/journal.pone.0032245.t001
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All mice were kept on a reverse light dark cycle. Behavioral tests
were performed during the dark period when animals were most
alert. Independent cohorts were used for the baseline open-field
and drug challenge open-field studies. Only male mice were used
for behavioral studies.
Open-field test. The open-field test was used to assess
animals’ locomotor activity. Animals (n=9–15 for each genotype)
were placed in one of the five square open field boxes 43643 cm
2
with two sets of 16 pulse-modulated infrared photobeams (MED
Associates) that records the animal’s location and path (horizontal
activity), as well as the number of rears (vertical activity) located
inside sound-attenuating cabinets with fans. Illumination of the
test room was the same as the mouse colony room. Mice were
examined at 6 months, 9 months and 12 months of age. For
baseline experiments, mice were placed in the open-field chamber
for 60 minutes. Data were analyzed as distance traveled (cm) and
rearing in 5-minute bins over time.
Rotarod. Rotarod (Ugo Basile, model 47600) was used to assess
the mouse’s ability to maintain balance and coordination (n=10–15
for each genotype). The apparatus consists of five 3 cm diameter
drums with six flanges dividing the drum, accommodating up to five
mice.Mice were placed in one of the five allocatedslots on the rotarod
and latency to fall was measured. There were two components to this
test – training and challenge. Rotarod training occurred over 3
consecutive days. For training, animals were placed on the rotarod as
it accelerated from 4 rpm to 40 rpm over 6 minutes. The trial ended
when the mice either fell off the rod or 400 seconds elapsed. Four
trials were performed on each of the three days. On the testing day,
mice were placed on the rotarod at 3 different fixed speeds, 4 trials per
speed, for a total of 12 trials. On this day, the trial ended when the
mouse fell off the rod or 300 seconds elapsed.
Balance Beam. Mice were trained to cross a square 80 cm
long sanded plastic beam 5 mm wide, which was elevated 50 cm
above base level (n=9–14 for each genotype). At the start of each
trial, mice were placed on clear open platform. A dark box at the
opposite end of the beam provided motivation for the mouse to
cross the beam. Traversal time and number of foot slips were
measured as mice traversed the beam. Mice were tested daily with
two trials on four consecutive days. The protocol was adapted
from Shokkattai and colleagues [20].
Drug Treatment
Three drugs dissolved in saline were administered by i.p injection
– scopolamine, GBR1290 and quinpirole. All drugs were purchased
from Sigma. Animals’ locomotor and rearing activities were
monitored following a 30-minute habituation period and immedi-
ately after drug injection for the locomotor activating drugs:
scopolamine(1.0 mg/kg,i.p.;n=10–14foreachgenotype receiving
drug) and GBR12909 (5.0 mg/kg, i.p.; n=5–8 for each genotype
receiving drug and 4–7 for each genotype receiving vehicle). For the
locomotor-depressing quinpirole (0.1 mg/kg, i.p.; n=10–11 for
each genotype receiving drug and 6–7 for each genotype receiving
vehicle), there was no habituation period prior to injection and
activity was monitored immediately after the challenge.
Data Analysis
The effects of strain on lifespan of Tor1a
DE/DE mice were
analyzed with survival curves using the Kaplan and Meier method
created with GraphPad Prism 4.0. Two or more survival curves
were compared using the logrank test, and Chi-square test was
used to generate p values.
Behavioral data were subject to tests for homogeneity (Leveine
test) and normal distribution (Kolmogorov-Smirnov test). All data
were analyzed with the Student t-test, repeated measure ANOVA,
or two-way ANOVA. Nested repeated measure ANOVA was used
when data were collected in multiple trials in more than one
session. For repeated measure ANOVA, all data were also subject
to Mauchly’s sphericity test, and F-ratios adjusted if violation
occurred. All statistical analyses were performed using SPSS 19.0.
A critical value for significance of p,0.05 was used throughout the
study. Data are plotted 6 SEM.
Results
Genetic background modifies the phenotype of mutant
torsinA (Tor1a
DE/DE) mice
To test for the presence of genetic modifiers of the DE-torsinA
phenotype, we pursued a two-step strategy. We first intercrossed
the 129-Tor1a
DE/+ mice with B6, D2 or CD1 wildtype mice. These
strains were chosen because they are genetically dissimilar from
each other and from 129 [21]. We then intercrossed the F1 129/
‘‘X’’ heterozygous offspring and assessed the phenotype of the
homozygous F2 Tor1a
DE/DE offspring. On average, these offspring
will be 50% 129 and 50% novel strain. All strains yielded F2
progeny in the expected Mendelian ratios, indicating that D2 or
CD1-ICR genes do not alter the ability of Tor1a
DE/DE animals to
survive through gestation and birth. The resulting litters were
observed twice daily during the first two postnatal (P) days and
once daily thereafter to determine the duration of survival. All
pups were genotyped at death or between P2 and P3 and any
remaining Tor1a
DE/DE animals were monitored. Tor1a
DE/DE mice
on 129 (n=21), 129/B6 (n=26), 129/D2 (n=53) and 129/CD1
(n=20) backgrounds were generated and closely observed.
We find that each of the three background strains has a distinct
effect on the DE-torsinA phenotype. 129/D2 Tor1a
DE/DE mice live
significantly longer than 129-Tor1a
DE/DE mice. The D2 background
significantly increases median survival to 3.5 days, compared to 1.5
days on 129 background (x
2(1)=14.60; p,0.0001 (129 vs 129/D2);
Figure 1A). The longest-surviving 129/D2 Tor1a
DE/DE animal lived
for21days,and13.2%livelongerthan7days.Micethatlivethrough
the end of the first postnatal week develop abnormal motor behavior,
exhibiting tremor and prolonged twisting movements during gait,
particularly of the hindlimbs (Figure 1C; Video S1). To test whether
we could further enhance the lifespan of 129/D2 Tor1a
DE/DE mice,
we continued to backcross the DE mutation for 10 generations onto
the D2 background. However, we find that F10 D2?Tor1a
DE/DE mice
do not live significantly longer than mice on the 129 background
(x
2(1)=0.62; p=0.43). In contrast to the D2 background, the B6
background significantly decreases median lifespan to 0.5 days
(x
2(1)=16.31; p,0.0001 (129 vs. 129/B6)). The CD1 background
also significantly alters lifespan, increasing the median survival from
1.5 days (pure 129) to 2.5 days (x
2(1)=5.207; p,0.05 (129 vs CD1/
129). Unlike D2 background effect, however, all Tor1a
DE/DE animals
d i eb yP3 . 5 .T h e s ed a t aa r ec o n si s t e n tw i t he x i st e n c eo fg e n e t i cf a c t o r s
that modify the DE-torsinA related phenotypes (Figure 1A).
Interestingly, we do not find an effect of D2 background on NE
bleb formation. Examination of various brain regions from E18.5
129/D2 and 129-Tor1a
DE/DE embryos reveals similar percentages
of NE bleb formation (129/D2% vs. 129% as follows): cortex (8%
vs. 7%), striatum (6% vs. 1.2%), and cerebellum (71% vs. 81%;
n=2 for each genetic background; Figure S1).
Gene sequencing for polymorphism (Aspartic acid/
Histidine 217)
The only genetic factor linked to the penetrance of the DE-
torsinA phenotype in humans is a coding polymorphism of torsinA
itself. Penetrance for DE-torsinA gene carriers whose wild type
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35% for the more common aspartic acid (D) at the same position
[22,23]. However, this polymorphism cannot account for the effects
of the D2 or B6 background, since in congenic Tor1a
DE/DE mice,
both Tor1a-DE alleles derive from the original 129 ES cell line used
for gene targeting. It could however, account for any behavioral
differences that may be observed in the heterozygous disease state
Tor1a
DE/+ mice. Therefore, we sequenced the Tor1a allele from 129,
B6 and D2 mice to determine whether there were differences at this
position (217 in the mouse protein) that would inform our choice of
background strain for modeling the disease in heterozygous mice.
We find that all three strains carry an aspartic acid (D), preventing
us from exploiting this polymorphism in this context (Figure 1B).
B6?Tor1a
DE/+ (DYT1) mice do not have baseline motor
abnormalities
The contribution of genes from the B6 strain of mice
significantly shortened lifespan in the resulting F2 129/B6
Tor1a
DE/DE mice (compared to the pure 129 background).
Therefore, we did all behavioral analysis on congenic B6?Tor1-
a
DE/DE mice with the rationale that this more susceptible strain
might reveal motor abnormalities we did not observe previously in
heterozygous Tor1a
DE/+ mice on the 129 background (there are no
significant differences in open field or rotarod between 129-
Tor1a
DE/+ and 129-Tor1a
+/+ mice at 6, 9, and 12 months of age –
n=16 WT and 14 mutants; data not shown). While we realize
that the decreased lifespan may be the result of an interaction
between 129 and B6 genes, we chose to backcross the 129
Tor1a
DE/+heterozygous mice to the B6 background to reduce any
background noise that may occur on a mixed background.
Furthermore, for all behavioral testing we only used adult mice
greater than 3 months of age to ensure that any developmentally
dependent phenotype would be fully manifest.
Open field. To test motor activity in B6?Tor1a
DE/+ mice, we
placed naı ¨ve male mice in the open field and measured horizontal
and rearing locomotor activity over 60 minutes. This assessment
was performed at 6, 9 and 12 months of age (n=10 Tor1a
+/+ and 9
Tor1a
DE/+ at 6 months; n=15 Tor1a
+/+ and 10 Tor1a
DE/+ mice at
9 and 12 months of age). No significant differences were observed
between B6?Tor1a
DE/+ and B6?Tor1a
+/+ mice at any of the ages
tested. All animals habituated to the open field at the same rate
and performed similarly as assessed by total distance traveled and
total rearing (Figure 2A–I).
Rotarod. To assess balance and coordination we performed
rotarod testing at 12 months of age (n=15 Tor1a
+/+ and 10
Tor1a
DE/+mice). The ability to perform this task is measured by
assessing the latency to fall from the rotarod (with longer latency
representing improved performance). During the three-day
training component of the task (2 trials per day), both groups of
mice exhibited significant improvement on the accelerating
Figure 1. Mouse background modulates lifespan of Tor1a
DE/DE mice. A. Kaplan-Meier survival curves of Tor1a
DE/DE mice. D2, B6 and CD1-ICR
genes modulate lifespan in Tor1a
DE/DE mice compared to original 129 background (Chi-square test used to generate p values: p,0.0001 for 129
versus 129/D2, 129/C57; p,0.05 for 129 versus 129/CD1). B. CLUSTALW2 multiple sequence alignment of genomic DNA from D2, B6, and 129
wildtype mice and Refseq demonstrates that all three strains have aspartic acid (D) at position 217 (*) of the mouse torsinA protein; figure depicts
base pairs which correspond to the amino acid coding sequence 212–221 (AERITDVALD) C. Long-lived F2 129/D2 Tor1a
DE/DE mouse and Tor1a
+/+
littermate. 129/D2 Tor1a
DE/DE mouse is smaller than control at postnatal day 14 (a.), poorly groomed with partially closed eyes (b.), exhibits improper
limb placement (c.), and demonstrates hindlimb clasping on tail suspension tests (d., e.).
doi:10.1371/journal.pone.0032245.g001
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indicating that both genotypes learned the task at the same rate.
Similarly, there was no significant difference in performance on
the ‘‘testing day’’ when the animals are tested at the fixed speeds of
40 rpm, 35 rpm and 30 rpm (4 trials per speed). These data
demonstrate that in the rotarod task, the DE mutation does not
significantly impair motor learning or gross motor skills such as
balance and coordination (Figure 2J–K).
Beam-walking test. To further assess fine motor behavior
and balance in the B6?Tor1a
DE/+mice, we used the beam-walking
paradigm. A separate cohort of seven-month old B6?Tor1a naı ¨ve
mice were trained to traverse a 5 mm square plexiglass beam on
two trials for three consecutive days, and latency to cross was
measured (with longer latency indicating impaired performance).
Latency to cross was measured for the training and testing days,
and on the fourth ‘‘testing day’’ we also quantified the number of
foot-slips. We noted a significant improvement in the time it took
for mice to traverse the beam (one-way rm-ANOVA, main effect
of day: F[2.83, 63]=10.12, p=0.00) however, no significant
difference was observed for latency between wild type (n=14) and
mutant mice (n=9) during training or on the testing day. Similar
to the findings for latency, no significant difference was observed
between wild type and mutant mice for foot-slips (Figure 2L–M).
B6?Tor1a
DE/+ (DYT1) mice do not display altered
responses to drug challenges
Anti-muscarinic drugs can be effective in treating the symptoms of
DYT1 dystonia and DYT1-torsinA transgenic mice are reported to
show an abnormal interplay between the dopaminergic and
cholinergic systems in electrophysiological studies [24,25,26]. To
probe these neurochemical systems, we challenged Tor1a
+/+ and
Tor1a
DE/+mice with the muscarinic receptor antagonist, scopolamine,
and the dopamine transporter reuptake inhibitor, GBR12909,
measuring the behavioral response to these drugs in the open field.
Scopolamine. Following a 30-minute habituation period in
the open field, we find no significant difference in the ability of
scopolamine (1.0 mg/kg) to stimulate either horizontal or rearing
locomotor behavior in B6?Tor1a
DE/+or B6?Tor1a
+/+ mice (n=14
Tor1a
+/+ and 10 Tor1a
DE/+mice; Figure 3A–C).
GBR12909. Similar to our results with scopolamine, following
habituation we find no significant difference in the ability of
GRB12909 (5.0 mg/kg, i.p.) to alter horizontal/rearing behavior
in B6?Tor1a
DE/+or B6?Tor1a
+/+ mice (n=5 Tor1a
+/+ and 8
Tor1a
DE/+ mice for drug group and 7 Tor1a
+/+ and 4 Tor1a
DE/+
mice for vehicle groups; Figure 3D–F).
Quinpirole. Since dopaminergic pathophysiological effects
described in transgenic animals have been attributed to D2
dopamine receptor function, we also challenged mice with
quinpirole (0.1 mg/kg, i.p.), a selective D2 dopamine receptor
antagonist. We find no difference in the effect of quinpirole
on horizontal/rearing locomotor activity in B6?Tor1a
DE/+or
B6?Tor1a
+/+mice (n=10 Tor1a
+/+ and 11 Tor1a
DE/+mice for drug
groups, 7 Tor1a
+/+ and 6 Tor1a
DE/+mice for vehicle groups;
Figure 3G–I).
Discussion
Our study is the firstto investigate the effects of genetic background
on the phenotype of torsinA mutant mice, a feature of particular
interest because of the reduced penetrance of the disease, some of
which may relate to genetic modifiers in the human population. We
identified background strains that are able to suppress (D2 and CD1)
or enhance (B6) the lethality of 129-Tor1a
DE/DE mice. These genetic
backgrounds produced survival times ranging fromless than12 hours
to up to 3 weeks, depending on the parental strains used for the F2
intercross (Figure 1). Future mapping of the genes responsible for
these effects may provide insight into the torsinA pathway, which
remains poorly understood. Alternatively, it is possible that these
variants alter lifespan independently of the torsinA pathway, for
example by making the pups more (or less) able to withstand the
effects of torsinA dysfunction.
A barrier to progress in dystonia research is the lack of an
animal model with overt abnormal movements, and a key aim of
our experiments was to identify background strains that might
enable us to develop such a model. Strikingly, the long-lived
D2?Tor1a
DE/DE pups exhibited a noticeable tremor, abnormal
limb placement and limb weakness, and a delayed righting reflex
(Video S1). While this abnormal motor behavior likely results from
torsinA-related neural dysfunction, these pups do not feed well and
appear generally ill, a confounding factor that complicates the
interpretation of this phenotype. This finding was nevertheless
encouraging, and we tried to build on it to create healthy mice that
display abnormal motor function (like the disease). Since an
increase from one to two mutated torsinA alleles causes early
lethality in the majority of mice, we tried to temper this phenotype
by further backcrossing to the apparently more permissive D2
background and analyzing D2?Tor1a
DE/DE mice. The variability
and enhanced lifespan diminished when Tor1a
DE/+ animals were
backcrossed more than 10 generations to a congenic D2
background. In fact, the lifespan of Tor1a
DE/DE on the D2
background was indistinguishable from those on the original 129
background. These findings indicate that the extended lifespan of
F2 129/D2 mice was due to a combination of homozygous and
heterozygous allelic effects. The debilitated nature of these mice
precluded further study of these animals.
We find that 129-Tor1a
DE/+ mice have no apparent behavioral
abnormalities. Because the B6 background significantly decreased
the survival of torsinA mutant mice, we explored whether this
background would enable us to detect phenotypic effects of the DE
Figure 2. B6?Tor1a
DE/+ mice do not have baseline motor abnormalities. Male B6?Tor1a
DE/+and B6?Tor1a
+/+ animals were monitored for gross
motor abnormalities. Horizontal activity in the open field for 60 min (5 min per point) sessions at 6 mos (A), 9 mos (D), and 12 mos of age (G) does not
differ between genotypes, rm-ANOVA, (F[11,187]=1.266, p=0.25 at 6 mos; F[4.67,107.5]=1.88, p=0.11 at 9 mos; F[5.02,115.52]=1.56, p=0.18 at 12
mos). Total distance traveled and total rearing over 60 min are shown as bargraphs (B, C, E, F, H, I). Each bar represents the mean of total activity over
one hour. Assessment of total horizontal distance traveled and total rearing by student’s T-test, also found no difference between genotypes at any
of the observed ages total distance: t[17]=1.40 ; p=0.18, at 6 mos; t(23)=0.84, p=0.92, at 9 mos; t[23]=0.65, p=0.52, at 12 mos (B, E, H), and for
total rearing: t[17]=0.62, p=0.54, at 6 mos; t[23]=20.90, p=0.38, at 9 mos; t[23]=20.90, p=0.38 at 12 mos (C, F, I). (J) One year old B6?Tor1a
DE/+and
B6?Tor1a
+/+ mice learn at the same rate during the three consecutive training days on the accelerating rotarod, rm-ANOVA, significant main effect of
training day F[2, 46]=72.06, p=0.00 but do not perform differently (no interaction between training day and genotype: F[1.57, 46)]=1.25, p=0.29).
(K) Both groups perform the same on the testing day (3 fixed speeds, 4 trials each), rm-ANOVA: no interaction between speed and genotype
(F[1,23]=0.91 (p=0.35). (L) Seven month old B6?Tor1a
DE/+and B6?Tor1a
+/+ mice perform similarly on the balance beam. Latency to cross the 5 mm
square beam is shown for 4 consecutive days (2 trials/day), rm-ANOVA: main effect of day: F[2.83, 63]=10.12 (p=0.00), no interaction between day
and genotype, F[3,63]=0.83 (p=0.48). (M) The number of footslips is shown for the last day of testing and no difference is found, T[20.85]=1.16;
(p=0.26).
doi:10.1371/journal.pone.0032245.g002
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B6?Tor1a
DE/+ mice and tested them in several behavior paradigms:
open field (with and without pharmacological challenge), rotarod,
and balance beam. Similar to the 129S6/SvEvTac background,
however, there were no significant differences between Tor1a
DE/+
and Tor1a
+/+ on the B6 background.
A previous study of Tor1a
DE/+ mice on a mixed 129/B6
background reported hyperactivity (significantly increased distance
traveled) in a 10-minute open field test and normal rearing activity
[15]. Interestingly, we find a trend in the opposite direction, with
B6?Tor1a
DE/+ mice appearing hypoactive during the first 5 min-
utes of the open field test, (p=0.05). Dang et. al. also measured
Figure 3. B6?Tor1a
DE/+ mice do not respond differently to pharmacological challenges in the open-field. Locomotor activity of
B6?Tor1a
DE/+ and B6?Tor1a
+/+ mice was monitored for 90 minutes (5 min per point) total. After a 30 minute habituation period, mice were injected
with (A) scopolamine (1.0 mg/kg) or (D) GBR12909 (5.0 mg/kg) or vehicle (indicated by arrow) and monitored for an additional 60 minutes.
Scopolamine and GBR12909 stimulated locomotor activity of both genotypes but there was no interaction between genotype and drug.
Scopolamine challenge, rm-ANOVA reveals no main effect of genotype and no significant interaction between time and genotype (F[2.52,
55.35]=1.05, p=0.37) of horizonal activity in the openfield (A). When totaled over the entire time in the openfield, there is no significant effect of
genotype on total horizontal distance, t[22]=0.040, (p=0.97) or total rearing t[22)]=20.143, (p=0.86; B–C). GBR challenge, rm-ANOVA demonstrated
a significant main effect of drug, F[1,25]=7.39, p=0.01, but no significant main effect of genotype (F[1,25]=.287, p=0.60) and no significant
interaction between drug and genotype (F[1,25]=0.08, p=0.78; D). Evaluation of total horizontal distance and total rearing with two-way ANOVA
finds significant main effect of drug (F([1,20]=16.02, p=0.00 (total horizontal distance); F[1,21]=0.20, p=0.66 (total rearing)) but no interaction
between drug and genotype (F[1,20]=1.46, p=0.24 (total horizontal distance); F[1,21]=0.50, p=0.49 (total rearing; E–F). (G) Quinpirole (0.1 mg/kg)
was injected at the start of the open field session and locomotor activity was monitored for 120 minutes. Quinpirole inhibited locomotor activity of
both groups of mice compared to vehicle but did not elicit a significant difference between genotypes. Rm-anova demonstrated a significant main
effect of drug F[1,29]=13.65, p=0.001, a significant main effect of genotype (F[1,29]=0.28, p=0.05), but no significant interaction between drug and
genotype (F[1,29]=0.28, p=0.06). (H–I) Examination of total horizontal distance and total rearing with two-way ANOVA finds a significant main effect
of drug (F[1,30]=11.330, p=0.002 (total horizontal distance); F[1,30]=9.68, p=0.004 (total rearing)) but no interaction between drug and genotype
(F[1,30]=0.74. p=0.40 (total horizontal distance); F[1,30]=0.20, p=0.66 (total rearing).
doi:10.1371/journal.pone.0032245.g003
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that wild type and mutant mice perform equally well on the
rotarod, however mutant mice show significantly more footslips
than controls on the balance beam test. There was no difference in
latency to cross the beam, however. There were some differences
in the execution of experiments between our studies presented
here and those of Dang et al. First, we examined spontaneous
locomotor activity in the open field in 5-minute bins for
60 minutes, while Dang et al. examined only the first 10 minutes.
Second, Dang et al. examined balance and coordination with
several different sized beams on the beam walking test (both
square and round beams ranging in size from 17 mm diameter/
width to 7 mm width, while we trained and tested mice on a more
difficult 5 mm width square beam. These data, and our finding of
normal behavior in the open field and beam walking suggest that
DE-torsinA may cause subtle behavioral abnormalities. However,
it is also possible that the confounding effects of mixed background
are responsible for the subtle abnormalities identified by Dang et al.
There arelimitationsofgeneticbackcrossingthatmayberelevant
to studies of torsinA. Although nearly all loci become homogenous
by approximately the tenth generation of backcrossing, the mutated
allele and closely linked flanking sequence from the original
background persist. With each successive backcross the flanking
sequence surrounding the gene of interest shortens, but frequently
several MB of the original background remain. TorsinB (a close
homolog of torsinA) is located adjacent to torsinA, so all of the
backgrounds tested almost certainly carry the original 129-torsinB
allele.A previousstudy demonstratedthat torsinAandtorsinBshare
redundant functions in multiple cell types, raising the possibility that
torsinB influences disease penetrance [9]. This may explain, at least
in part, the absence of a behavioral phenotype in Tor1a
DE/+ mice.
Similar considerations pertain to the one reported genetic
modifier of disease penetrance in DYT1 dystonia. A non-
synonymous SNP in the coding sequence for residue 216 encodes
aspartic acid (D) in 88% and histidine (H) in 12% of control
population alleles, and the D216H allele is reported to significantly
reduce disease penetrance when present in the normal allele in
trans to the mutated allele [23,27]. We found the ‘‘D’’ allele at the
analogous murine residue (217) in all of the strains used in this
study, further demonstrating the highly conserved features of the
Tor1a gene and indicating that this SNP does not affect penetrance
in Tor1a
DE/+ mice. Several other SNPs are present in the 59 and 39
UTR regions of TOR1A, as well as a single-base-pair deletion in
the 39 UTR (G-del), but these features are not known to be
associated with the penetrance of DYT1 dystonia. On the other
hand, several SNPs in the 39 UTR may influence the onset and
propensity to spread in adult-onset primary dystonia [28,29].
Etiological animal models (i.e., those based on known causes of
human disease) may offer insight into disease pathogenesis even if
they do not replicate the outward symptoms of the disease. In fact,
diffusion tensor imaging (DTI) of B6?Tor1a
DE/+mice demonstrates
microstructural abnormalities in the cerebellothalamocortical and
thalamocortical tracts [22] similar to those observed in non-
penetrant DYT1 carriers [6,30,31] indicating that these mice
model non-manifesting carriers. Thus, while genetic modifiers
seem likely to account for at least part of variable penetrance and
expressivity of the DE-Tor1a allele, additional factors may be
required to convert Tor1a
DE/+mice (or patients) from non-
manifesting to overt disease. For example, stress exposure or
excessive motor activity (e.g., prolonged wheel running) may be
required ‘‘second hits’’. Future studies aimed at identifying such
factors will therefore be required to generate torsinA mutant mice
that exhibit abnormal movements, a critically needed reagent if we
are to use animal models to dissect the neurobiological substrates
of dystonic movements.
Supporting Information
Figure S1 Tor1a
DE/DE mice exhibit similar neuronal NE
blebbing ultrastructure on the 129 and 129/D2 back-
ground at age E18.5. Nuclear envelope abnormalities previously
described are apparent at E18.5 in cortex of Tor1a
DE/DE mice when
viewed by electron microscopy. A. Normal E18.5 cortical neuronal
nuclear envelope. B. Abnormal NE with bleb visible between inner
and outer nuclear membrane in 129-Tor1a
DE/DE mouse cortical
neuron. C. Abnormal NE with bleb visible between inner and outer
nuclear membrane in 129/D2?Tor1a
DE/DE mouse cortical neuron.
Scale bars, 500 nm. N, nucleus; C, cytosol.
(TIF)
Video S1 Long-lived postnatal day 8 129/D2 Tor1a
DE/DE
mouse and littermate. 129/D2 Tor1a
DE/DE mice are strikingly
smaller compared to littermate controls and exhibit obvious motor
dysfunction, including tremor, improper limb placement, and
limited balance.
(MOV)
Acknowledgments
We are grateful to Dr. Miriam Meisler for helpful comments and
suggestions regarding the manuscript. We thank Kana Meece (Columbia
University) and Huilin Lee (University of Michigan) for their expert help
with mouse colony maintenance and genotyping, Dr. Julie Jones (Meisler
lab) for contributing D2 mouse genomic DNA and guidance with genomic
DNA sequencing, and Dr. Maria do Carmo Pereira da Costa for help and
advice on the design of the balance beam experiments. We also thank
Hong Yi and her colleagues at the Emory University Robert P. Apkarian
Integrated Electron Microscopy Core for outstanding electron microscopy
sample preparation.
Author Contributions
Conceived and designed the experiments: LT WD. Performed the
experiments: LT CM. Analyzed the data: LT CM. Contributed
reagents/materials/analysis tools: WD. Wrote the paper: LT WD.
References
1. Tanabe LM, Kim CE, Alagem N, Dauer WT (2009) Primary dystonia:
molecules and mechanisms. Nat Rev Neurol 5: 598–609.
2. Ozelius L, Kramer PL, Moskowitz CB, Kwiatkowski DJ, Brin MF, et al. (1989)
Human gene for torsion dystonia located on chromosome 9q32–q34. Neuron 2:
1427–1434.
3. Ozelius LJ, Page CE, Klein C, Hewett JW, Mineta M, et al. (1999) The TOR1A
(DYT1) gene family and its role in early onset torsion dystonia. Genomics 62:
377–384.
4. Eidelberg D, Moeller JR, Antonini A, Kazumata K, Nakamura T, et al. (1998)
Functional brain networks in DYT1 dystonia. Ann Neurol 44: 303–312.
5. Trost M, Carbon M, Edwards C, Ma Y, Raymond D, et al. (2002) Primary
dystonia: is abnormal functional brain architecture linked to genotype? Ann
Neurol 52: 853–856.
6. Argyelan M, Carbon M, Niethammer M, Ulug AM, Voss HU, et al. (2009)
Cerebellothalamocortical connectivity regulates penetrance in dystonia.
J Neurosci 29: 9740–9747.
7. Niethammer M, Carbon M, Argyelan M, Eidelberg D (2011) Hereditary
dystonia as a neurodevelopmental circuit disorder: Evidence from neuroimag-
ing. Neurobiol Dis 42: 202–209.
8. Nadeau JH (2005) Listening to genetic background noise. N Engl J Med 352:
1598–1599.
9. Kim CE, Perez A, Perkins G, Ellisman MH, Dauer WT (2010) A molecular
mechanism underlying the neural-specific defect in torsinA mutant mice. Proc
Natl Acad Sci U S A 107: 9861–9866.
10. Goodchild RE, Dauer WT (2005) The AAA+ protein torsinA interacts with a
conserveddomainpresentinLAP1andanovelERprotein. JCellBiol168:855–862.
Genetic Background Modulates DYT1 Dystonia Mouse
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e3224511. Giles LM, Li L, Chin LS (2009) Printor, a novel torsinA-interacting protein
implicated in dystonia pathogenesis. J Biol Chem 284: 21765–21775.
12. Sharma N, Baxter MG, Petravicz J, Bragg DC, Schienda A, et al. (2005)
Impaired motor learning in mice expressing torsinA with the DYT1 dystonia
mutation. J Neurosci 25: 5351–5355.
13. Shashidharan P, Sandu D, Potla U, Armata IA, Walker RH, et al. (2005)
Transgenic mouse model of early-onset DYT1 dystonia. Hum Mol Genet 14:
125–133.
14. Grundmann K, Reischmann B, Vanhoutte G, Hubener J, Teismann P, et al.
(2007) Overexpression of human wildtype torsinA and human DeltaGAG
torsinA in a transgenic mouse model causes phenotypic abnormalities.
Neurobiol Dis 27: 190–206.
15. Dang MT, Yokoi F, McNaught KS, Jengelley TA, Jackson T, et al. (2005)
Generation and characterization of Dyt1 DeltaGAG knock-in mouse as a model
for early-onset dystonia. Exp Neurol 196: 452–463.
16. Goodchild RE, Kim CE, Dauer WT (2005) Loss of the dystonia-associated
protein torsinA selectively disrupts the neuronal nuclear envelope. Neuron 48:
923–932.
17. Cookson MR, Clarimon J (2005) Dystonia and the nuclear envelope. Neuron
48: 875–877.
18. Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, et al. (1997)
Behavioral phenotypes of inbred mouse strains: implications and recommenda-
tions for molecular studies. Psychopharmacology (Berl) 132: 107–124.
19. Kearney JA (2011) Genetic modifiers of neurological disease. Curr Opin Genet
Dev 21: 349–353.
20. Shakkottai VG, do Carmo Costa M, Dell’Orco JM, Sankaranarayanan A,
Wulff H, et al. (2011) Early changes in cerebellar physiology accompany motor
dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci
31: 13002–13014.
21. Beck JA, Lloyd S, Hafezparast M, Lennon-Pierce M, Eppig JT, et al. (2000)
Genealogies of mouse inbred strains. Nat Genet 24: 23–25.
22. Bressman SB (2007) Genetics of dystonia: an overview. Parkinsonism Relat
Disord 13 Suppl 3: S347–355.
23. Risch NJ, Bressman SB, Senthil G, Ozelius LJ (2007) Intragenic Cis and Trans
modification of genetic susceptibility in DYT1 torsion dystonia. Am J Hum
Genet 80: 1188–1193.
24. Pisani A, Martella G, Tscherter A, Bonsi P, Sharma N, et al. (2006) Altered
responses to dopaminergic D2 receptor activation and N-type calcium currents
in striatal cholinergic interneurons in a mouse model of DYT1 dystonia.
Neurobiol Dis 24: 318–325.
25. Martella G, Tassone A, Sciamanna G, Platania P, Cuomo D, et al. (2009)
Impairment of bidirectional synaptic plasticity in the striatum of a mouse model
of DYT1 dystonia: role of endogenous acetylcholine. Brain 132: 2336–2349.
26. Napolitano F, Bonito-Oliva A, Federici M, Carta M, Errico F, et al. (2010) Role
of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32
signaling in the paradoxical calming effect of amphetamine. J Neurosci 30:
11043–11056.
27. Leung JC, Klein C, Friedman J, Vieregge P, Jacobs H, et al. (2001) Novel
mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and
polymorphisms in dystonia and early onset parkinsonism. Neurogenetics 3:
133–143.
28. Clarimon J, Asgeirsson H, Singleton A, Jakobsson F, Hjaltason H, et al. (2005)
Torsin A haplotype predisposes to idiopathic dystonia. Ann Neurol 57: 765–767.
29. Kamm C, Asmus F, Mueller J, Mayer P, Sharma M, et al. (2006) Strong genetic
evidence for association of TOR1A/TOR1B with idiopathic dystonia.
Neurology 67: 1857–1859.
30. Ulug AM, Vo A, Argyelan M, Tanabe L, Schiffer WK, et al. (2011)
Cerebellothalamocortical pathway abnormalities in torsinA DYT1 knock-in
mice. Proc Natl Acad Sci U S A 108: 6638–6643.
31. Carbon M, Su S, Dhawan V, Raymond D, Bressman S, et al. (2004) Regional
metabolism in primary torsion dystonia: effects of penetrance and genotype.
Neurology 62: 1384–1390.
Genetic Background Modulates DYT1 Dystonia Mouse
PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e32245